Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Katanin catalytic subunit A-like 2 (KATNAL2)
- Target
- KATNAL2
- Molecular classification
- Enzyme (ATPase, microtubule-severing), AAA family ATPase
01
Overview
Katanin catalytic subunit A-like 2 (KATNAL2) is a member of the AAA ATPase family and functions as a microtubule-severing enzyme, homologous to the archetypal katanin proteins. KATNAL2 plays essential roles in cellular and developmental processes by remodeling microtubule structures necessary for cell division, ciliogenesis, organogenesis, and spermatogenesis. It is expressed in ciliated and neurogenic tissues, localizing to basal bodies, centrioles, mitotic spindles, and ciliary axonemes. Loss or malfunction of KATNAL2 disrupts cilia formation, cell cycle, and cell polarity, and is associated with male infertility and neurodevelopmental disorders, including autism spectrum disorder. KATNAL2 may interact with other regulatory proteins (e.g., KATNB1, NUBP1/2), further modulating its cellular roles. There are no known directly targeting therapeutic agents; however, its disease associations make it a candidate for future research as a therapeutic target or biomarker[1][2][3].
- Other names
- Katanin p60 ATPase-containing subunit A-like 2KATNAL2Katanin p60 subunit A-like 2MGC33211DKFZP667C165p60 katanin-like 2
02
Mechanism of action
No drugs target KATNAL2 directly; general mechanism for microtubule-severing enzymes involves ATP-dependent severing of microtubules[1][2][3].
03
Biological functions
Microtubule severing and remodelingCiliogenesis (formation of cilia)Cell cycle progressionCytokinesisSpermatogenesisBrain developmentRegulation of microtubule dynamicsCell polarity
04
Disease associations
Neurodevelopmental disease (risk gene for autism spectrum disorder[1])Male infertility (mutations affect spermatogenesis and sperm maturation[2])Other (potential links to defective organogenesis, cell cycle, and cilia-related pathologies)
05
Safety considerations
Potential toxicity of modulating microtubule dynamics (microtubule severing is fundamental to cell structure, division, and differentiation; off-target effects could disrupt essential cellular processes[3].)Developmental defects (implicated in organogenesis and neurodevelopment; therapeutic modulation may cause broad developmental abnormalities[1].)
06
Biomarkers
KATNAL2 mutations or expression change may serve as research biomarkers for autism spectrum disorders or male infertility but are not established clinical biomarkers[1][2].
Beyond the preview
Go deeper on Katanin catalytic subunit A-like 2 (KATNAL2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Katanin catalytic subunit A-like 2 (KATNAL2).